Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | 24.48K | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -2.39M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -3.14M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 3.57M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 613.50K | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.31M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 5.31M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -2.72M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -2.70M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | 81.07K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 4.63M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$15.10M | -3.26 | -27.84% | ― | 6.77% | -8.45% | |
55 Neutral | AU$74.13M | -8.12 | -8647.54% | ― | 25.98% | 22.10% | |
52 Neutral | AU$23.25M | -12.89 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | AU$43.43M | -9.29 | -81.30% | ― | -36.68% | 79.41% | |
40 Underperform | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Emyria Ltd Corporate Events
Emyria Ltd has announced the application for the quotation of 76,443 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to enhance its financial positioning and operational capabilities, potentially impacting its market presence and stakeholder interests.
Emyria Limited has announced the issuance of 133,333,334 new fully paid ordinary shares at an issue price of $0.06 per share, raising $8 million before costs. This capital raise allows the shares to be traded immediately under the exemption of section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially impacting the company’s market position.
Emyria Ltd has announced the quotation of 217,725 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and operational capacity, potentially strengthening its position in the healthcare market and offering new opportunities for stakeholders.
Emyria Ltd has announced the quotation of 133,333,334 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD, effective from November 28, 2025. This move follows previous transactions and is part of the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its operational dynamics and offering new opportunities for stakeholders.
Emyria Limited has announced the issuance of 916,667 new fully paid ordinary shares at an issue price of $0.05 per share following the exercise of options. This issuance allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, indicating compliance with relevant legal provisions and facilitating liquidity for stakeholders.
Emyria Ltd has announced the quotation of 1,388,316 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 21, 2025. This development is part of the company’s strategy to enhance its market presence and potentially increase its capital base, which could have significant implications for its stakeholders and industry positioning.
Emyria Ltd has announced a proposed issue of securities, including 10 million unlisted options and over 133 million ordinary fully paid shares. This move is part of a placement or other type of issue, with the proposed issue date set for November 28, 2025. The issuance is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion.
Emyria Limited has announced a significant expansion of its national presence by exercising an option to establish its first Empax Clinic in Victoria, marking a major milestone in its East Coast expansion. The company has secured exclusive rights to roll out Empax clinics across Avive Health’s network, enhancing its ability to provide intensive mental-health services nationwide. This expansion is supported by a successful $8 million institutional placement, which will accelerate the development of new sites and expand the clinical workforce. Additionally, Emyria has commenced revenue generation at its Brisbane clinic and has received support from the Department of Veterans’ Affairs for medication-assisted therapy, establishing a dual reimbursement pathway with private insurers.
Emyria Ltd has announced the quotation of 730,114 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD. This move is part of the company’s strategy to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operational capacity and investor relations positively.
Emyria Limited announced that all resolutions presented at their Annual General Meeting were successfully carried by a poll. The resolutions included matters such as the remuneration report, election of a director, and approval of a 10% placement facility, among others. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic initiatives.
Emyria Ltd has announced the quotation of 322,976 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 7, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and providing new opportunities for stakeholders.
Emyria Ltd has announced the cessation of 300,000 securities due to the expiry of options that were not exercised or converted by November 1, 2025. This development may affect the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s financial instruments.
Emyria Limited has reported significant growth in revenue and operational expansion in its quarterly activity report for September 2025. The company has expanded its agreement with Medibank to include insurer-funded access to its mental health treatment programs for PTSD and TRD in both Perth and Brisbane. This expansion marks the first national rollout of insured mental health treatment programs in Australia, demonstrating strong insurer confidence in Emyria’s care model. The company has also increased its workforce and treatment capacity to support growing demand, with plans to commence patient dosing in Brisbane by late Q4 2025. Emyria’s strategic partnerships and scalable model position it as a leader in evidence-based mental health care, with ongoing commercial momentum and broader national rollout plans.
Emyria Ltd has announced the quotation of 278,113 fully paid ordinary securities on the Australian Securities Exchange (ASX), following the exercise of options or conversion of other convertible securities. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operations and positioning within the healthcare sector.
Emyria Limited has announced the issuance of 845,979 new fully paid ordinary shares at an issue price of $0.05 per share, following the exercise of options. This move allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially strengthening the company’s financial position. The announcement signifies Emyria’s compliance with relevant legal provisions, ensuring transparency and adherence to corporate governance standards.
Emyria Ltd has announced the quotation of 2,524,780 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 17, 2025. This move signifies a strategic step for Emyria in expanding its capital base, potentially enhancing its market position and providing additional resources to further its healthcare initiatives.
Emyria Limited has announced a significant expansion of its services with a new funding agreement from Medibank Private Ltd. This agreement will allow eligible patients to access Emyria’s mental health programs for TRD and PTSD at the new Empax Clinic in Brisbane, marking the company’s first insurer-backed services on Australia’s East Coast. This expansion is part of Emyria’s national growth strategy to address the mental health burden in Australia by providing affordable and coordinated treatment options. The collaboration with Medibank is expected to reduce financial barriers for patients and demonstrates the scalability of Emyria’s care model, positioning the company as a leader in evidence-based mental health care.
Emyria Ltd has announced its involvement in addressing Australia’s mental health crisis through the development of advanced therapies, including the use of MDMA and psilocybin in psychedelic-assisted psychotherapy. While these treatments show promise, they are subject to clinical trials to ensure safety and efficacy, and currently, no approved products exist. The announcement highlights Emyria’s commitment to innovative mental health solutions, although it also underscores the risks and uncertainties inherent in developing such treatments.
Emyria Limited announced its participation in a live investor webinar hosted by Sharewise, where key executives will discuss the company’s latest developments and strategic outlook. The webinar will cover Emyria’s unique positioning in delivering evidence-based treatments, national expansion plans, and growth strategy, providing stakeholders with insights into the company’s future directions.
Emyria Ltd has announced the quotation of 112,610 ordinary fully paid securities on the ASX, effective October 10, 2025. This move signifies the company’s strategic efforts to enhance its capital structure and potentially increase its market presence, which could have implications for its stakeholders and industry positioning.
Emyria Ltd, a company listed on the ASX under the ticker EMD, is making significant strides in addressing serious mental illnesses. The company’s efforts are positively impacting the lives of patients and their communities, as highlighted by Executive Chairman Greg Hutchinson. This mission-driven approach underscores Emyria’s commitment to improving mental health outcomes.
Emyria Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, indicating a commitment to transparency and accountability in its management and oversight practices.
Emyria Ltd has announced its upcoming Annual General Meeting (AGM) for shareholders, scheduled for November 13, 2025, in West Perth, Australia. The company has opted for electronic distribution of the meeting materials, encouraging shareholders to vote by proxy if unable to attend in person. This move reflects a modern approach to shareholder engagement, potentially enhancing participation and operational efficiency.
Emyria Ltd has announced its Annual General Meeting (AGM) scheduled for November 13, 2025, at Stantons International in West Perth, Australia. The AGM will address the company’s annual report and include resolutions on the remuneration report and the election of Dr. Michael Winlo as a director. Shareholders are encouraged to participate and vote, with the meeting set to discuss key governance and strategic decisions impacting the company’s future direction.
Emyria Ltd announced the cessation of 75,000 securities due to the expiry of options or other convertible securities without exercise or conversion, effective October 7, 2025. This cessation of securities may impact the company’s capital structure and could have implications for stakeholders, particularly those holding or interested in these specific securities.
Emyria Ltd has announced a new issuance of 315,612 ordinary fully paid securities, which will be quoted on the ASX under the code EMD. This move is part of the company’s strategy to capitalize on convertible securities being exercised, potentially enhancing its financial position and market presence.
Emyria Ltd has announced a change in the director’s interest, specifically involving Mr. Greg Hutchinson. The change involves the acquisition of 10,663,691 unlisted options exercisable at $0.05 each, expiring on 22 March 2027. These options were issued as Loyalty Options to eligible shareholders, as per the company’s prospectus dated 8 September 2025. This move is part of Emyria’s strategy to reward its shareholders and potentially strengthen its market position by aligning the interests of its directors with those of its investors.
Emyria Ltd has announced the quotation of 516,616 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 30, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for future growth initiatives, reflecting its commitment to expanding its operations and influence in the healthcare sector.
Emyria Ltd has announced the issuance of 164,954,976 unquoted equity securities in the form of options with an exercise price of $0.05, set to expire on March 22, 2027. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, indicating a strategic move to potentially raise capital or incentivize stakeholders without immediate market exposure.
Emyria Ltd announced the cessation of 150,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may influence the company’s capital structure and could have implications for current and potential investors as it reflects changes in the company’s issued capital.
Emyria Limited has entered into a landmark multi-year agreement with Medibank Private Ltd to fund its Treatment-Resistant Depression (TRD) program at Perth Clinic. This agreement marks the first time a major Australian health insurer will fund a psychotherapy-led TRD program, significantly reducing financial barriers for eligible patients. This initiative builds on Medibank’s existing support for Emyria’s PTSD treatment program and further validates Emyria’s psychiatrist-led care model. With two funded programs now operational, Emyria is well-positioned for scalable growth and to make a lasting impact on mental health care in Australia.
Emyria Limited has successfully completed the sale of less than marketable parcels of shares to a consortium of specialist life sciences investors, achieving a 6.38% premium on the last traded share price. This strategic move not only validates Emyria’s growth trajectory and expansion strategy but also streamlines its shareholder register, reducing administrative costs and enhancing corporate efficiencies. The participation of strategic investors strengthens Emyria’s shareholder base and aligns with its goal to scale access to evidence-based mental health treatments across Australia.
Emyria Limited has announced a pro-rata bonus offer of unquoted Loyalty Options to incentivize eligible shareholders, providing them with an opportunity to participate in the company’s potential future success. The offer is limited to shareholders with registered addresses in Australia and New Zealand, excluding those outside these regions due to logistical and regulatory considerations.
Emyria Ltd has announced a pro-rata bonus offer of unquoted Loyalty Options to reward eligible shareholders, providing them with an opportunity to participate in the company’s future success. The offer, which involves issuing one Loyalty Option for every four shares held, aims to incentivize shareholder loyalty and facilitate secondary trading of shares issued upon the exercise of these options.
Emyria Ltd has announced a bonus issue of up to 166,040,206 unquoted Loyalty Options to eligible shareholders, with each option having an exercise price of $0.05. This issuance is part of a strategy to reward shareholders, with no action required from them to receive their options. The offer is speculative and is not available to investors outside Australia and New Zealand, which may impact the company’s shareholder engagement and market positioning.